STOCK TITAN
  1. Home
  2. News
  3. BNGO

Bionano Genomics, Inc. - BNGO STOCK NEWS

Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.

Bionano Genomics, Inc. (Nasdaq: BNGO) is a pioneering company in the life sciences instrumentation sector, dedicated to advancing genome biology understanding through innovative solutions. The company is renowned for its development and marketing of the Saphyr™ system, an ultra-sensitive platform designed for structural variation detection. This system enables researchers and clinicians to accelerate diagnostics and therapeutic target discovery, streamlining studies on chromosomal changes.

Bionano's core mission is to transform genomic analysis through optical genome mapping (OGM) solutions, diagnostic services, and software. Their flagship product, Saphyr™, offers unmatched capabilities in structural variation discovery and the ability to construct comprehensive genome assemblies. This technology is crucial for applications in cancer research, human disease studies, agricultural bioengineering, and genome discovery.

Recent achievements include the detection of unique structural variations and gene fusions in blood cancer samples, underscoring OGM's potential as a complement to traditional sequencing methods. Bionano's OGM technology has shown superior sensitivity and resolution in various studies, highlighting its utility in pediatric leukemia and other cancers.

The company operates globally with significant revenue from the Americas, and it generates product revenue from the sales of OGM and Ionic Purification systems and consumables. Bionano also offers diagnostic testing for neurodevelopmental disabilities through its Lineagen, Inc. d/b/a Bionano Laboratories business and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.

Partnerships with AI-driven companies like Diagens further enhance Bionano's offerings, aiming to improve reproductive health and other clinical applications. Additionally, Bionano continuously upgrades its VIA software and Bionano Solve pipeline to provide researchers with precise and sensitive genomic research tools.

For more information, visit Bionano Genomics and its associated websites, www.bionanolaboratories.com and www.purigenbio.com.

News

Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced a peer-reviewed publication in Cancers detailing the use of optical genome mapping (OGM) to discover structural variants (SVs) driving drug resistance and sensitivity in cancer. The study analyzed 26 leukemia samples, revealing drug sensitivities and resistances associated with genomic rearrangements. OGM detected all SVs observed using classical cytogenetic methods and additional variants. The findings suggest potential new treatment strategies for leukemia, with implications for drug development and personalized medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of the second interim report from an ongoing clinical trial designed to support establishing OGM as part of standard of care (SOC) in the diagnosis of genetic disease for prenatal subjects. The study demonstrated that OGM has high sensitivity, specificity, and overall accuracy, making it a promising alternative to classical cytogenetic methods in prenatal diagnosis. The results of the study show that OGM can provide results comparable to two or three separate standard of care tests with just a single assay, indicating its potential to streamline genetic analysis processes and provide rapid, cost-effective solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
clinical trial
-
News

Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) has announced the full commercial release of the Stratys™ system, a high throughput optical genome mapping (OGM) system. The Stratys instrument offers up to a four-fold increase in raw data generation rate compared to the Saphyr® instrument and can process up to 12 single access chips without the need to batch multiple samples on a consumable. The data analysis for the Stratys system is powered by Stratys™ Compute, developed in collaboration with NVIDIA. 10 users across Canada, the United States, Europe, and Saudi Arabia have adopted a total of 11 Stratys systems as part of an early access program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

Rhea-AI Summary
Bionano Genomics, Inc. announced its 2024 Symposium featuring 33 oral presentations by 26 customers worldwide, highlighting the utility of optical genome mapping across research applications in cancer, cell and gene therapy, and genetic disease. The 4-day virtual event will also unveil a new product. The company aims to bring the OGM community together to share research progress and drive further advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
News

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed publication detailing results from the second phase of a large multisite clinical study designed to support establishing optical genome mapping (OGM) as part of the standard of care (SOC) in diagnosis of genetic disease for postnatal patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
clinical trial
-
News

Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announces its 2024 Symposium, a virtual event featuring OGM presentations by 27 customers worldwide. The event will showcase applications in cancer, cell and gene therapy, and constitutional genetic disease. Bionano will also unveil a new product to advance cytogenetics and structural variant analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
none
News

Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) reported unaudited preliminary financial and commercial highlights for Q4 2023. Revenue expected to be $10.4-10.7 million, a 27-30% increase over Q4 2022. Installed base of OGM systems increased by 36%, and nanochannel array flowcells sold expected to increase by 67% over Q4 2022. Full year 2023 revenue expected to be $35.8-36.1 million, a 29-30% increase over 2022. Cash, cash equivalents, and available-for-sale securities as of December 31, 2023, were approximately $102.8 million. The company achieved all full-year 2023 ELEVATE milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
earnings
-
News

OGM Added to International System for Human Cytogenomic Nomenclature

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the addition of optical genome mapping (OGM) to the International System for Human Cytogenomic Nomenclature (ISCN). The OGM nomenclature is set to be published in the 2024 ISCN guide, providing a universal naming convention for genetic variants detected by OGM. This move is expected to enhance clear communication in publications and consistency in databases for genetic laboratories, marking a significant milestone for OGM and researchers using the workflow to advance molecular cytogenetics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
-
News

International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications

Rhea-AI Summary
Bionano Laboratories (Nasdaq: BNGO) announced the publication of the first framework paper for the clinical adoption and implementation of the optical genome mapping (OGM) workflow for hematological malignancy applications. The framework was co-authored by an international consortium of 18 cancer researchers and is intended to help laboratories with the uniform adoption and implementation of an OGM workflow. It includes recommendations for laboratories planning to adopt OGM on topics such as assay development, clinical validation, implementation, algorithms for data interpretation, and strategies for efficient reporting. The framework paper outlines specific recommendations in three areas: validation, quality control, and analysis and interpretation of variants. Bionano Laboratories developed its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne, based on the process outlined in this publication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
News

Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant upgrades to its VIA™ software, enhancing the sensitivity and specificity for structural variation (SV) detection from optical genome mapping (OGM) data, further advancing OGM’s leadership in variant detection. The latest analysis pipeline, Bionano Solve 3.8.1, also enables comprehensive visualization, interpretation, and reporting of SVs and CNVs from OGM data in constitutional genetic disease research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none

FAQ

What is the current stock price of Bionano Genomics (BNGO)?

The current stock price of Bionano Genomics (BNGO) is $0.2514 as of November 25, 2024.

What is the market cap of Bionano Genomics (BNGO)?

The market cap of Bionano Genomics (BNGO) is approximately 24.2M.

What does Bionano Genomics, Inc. specialize in?

Bionano Genomics specializes in genome analysis solutions, particularly through their Saphyr™ system for structural variation detection.

What is the Saphyr™ system?

The Saphyr™ system is Bionano's high-speed, high-throughput whole genome mapping solution that offers unmatched structural variation discovery capabilities.

What are the applications of Bionano's OGM technology?

Bionano's OGM technology is used in cancer research, human disease studies, agricultural bioengineering, and genome discovery.

What recent achievements has Bionano reported?

Bionano recently reported detecting unique structural variations and gene fusions in blood cancer samples, showcasing OGM's potential as a complement to traditional sequencing methods.

Where does Bionano operate?

Bionano operates globally with significant revenue generated from the Americas, EMEA, and Asia Pacific regions.

What additional services does Bionano offer?

Bionano offers diagnostic testing for neurodevelopmental disabilities and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.

Who are Bionano's key partners?

Bionano partners with companies like Diagens to enhance clinical applications, particularly in reproductive health.

What is the purpose of Bionano's VIA software?

Bionano's VIA software provides researchers with precise and sensitive tools for genomic research, improving visualization, interpretation, and reporting of results.

Are Bionano's products for research or clinical use?

Most of Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

How can I learn more about Bionano Genomics?

You can visit Bionano's main website at www.bionano.com or its associated websites, www.bionanolaboratories.com and www.purigenbio.com, for more information.

Stock BNGO logo
Bionano Genomics, Inc.

Nasdaq:BNGO

BNGO Rankings

#5222 Ranked by Market Cap
N/A Ranked by Dividends

BNGO Stock Data

24.17M
101.87M
0.15%
12.81%
10.25%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO